Stock Events

Stock Events

Galera Therapeutics 

$18.99
24
+$3.37+21.57% Monday 19:56

Statistics

Day High
18.5
Day Low
16
52W High
30
52W Low
3.02
Volume
1,277
Avg. Volume
472
Mkt Cap
1.43B
P/E Ratio
0.15
Dividend Yield
-
Dividend
-

Earnings

12AugExpected
Q4 2024
Q2 2026
-60
-59.67
-59.33
-59
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
149.05MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen develops therapies in areas overlapping with Galera's focus on cancer supportive care, making them direct competitors in the oncology market.
Merck
MRK
Mkt Cap366B
Merck's extensive portfolio in oncology, including treatments that mitigate side effects of cancer therapy, places it in competition with Galera Therapeutics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad range of oncology treatments and supportive care products that compete with Galera's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb's involvement in developing and marketing cancer supportive care drugs makes it a competitor to Galera Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, with its focus on innovative treatments in oncology, competes in the same space as Galera Therapeutics.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences' oncology and supportive care portfolio competes with Galera's focus on improving cancer treatment outcomes.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a wide range of oncology treatments, including those for side effects of cancer therapy, competing with Galera Therapeutics.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca's commitment to developing cancer therapies and supportive care solutions places it in direct competition with Galera.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly's portfolio in oncology and treatment of cancer side effects competes with Galera Therapeutics' focus areas.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries, through its generic and specialty medicines, including in oncology, competes with Galera Therapeutics' specialized treatments.

About

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Show more...
CEO
Dr. John Mel Sorensen M.D.
Employees
3
Country
United States
ISIN
US36338D1081

Listings

OTCM
US
GRTXD

0 Comments

Share your thoughts

FAQ

What is Galera Therapeutics stock price today?▼
The current price of GRTXD is $18.99 USD — it has increased by +21.57% in the past 24 hours. Watch Galera Therapeutics stock price performance more closely on the chart.
What is Galera Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Galera Therapeutics stocks are traded under the ticker GRTXD.
What is Galera Therapeutics market cap?▼
Today Galera Therapeutics has the market capitalization of 1.43B
What is Galera Therapeutics revenue for the last year?▼
Galera Therapeutics revenue for the last year amounts to 0 USD.
What is Galera Therapeutics net income for the last year?▼
GRTXD net income for the last year is 149.05M USD.
How many employees does Galera Therapeutics have?▼
As of September 02, 2026, the company has 3 employees.
In which sector is Galera Therapeutics located?▼
Galera Therapeutics operates in the Health & Wellness sector.
When did Galera Therapeutics complete a stock split?▼
The last stock split for Galera Therapeutics was on July 13, 2026 with a ratio of 1:200.
Where is Galera Therapeutics headquartered?▼
Galera Therapeutics is headquartered in Malvern, United States.